Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.


Related Content

Global Blood Takes HOPE In Sickle Cell After Pulmonary Fibrosis Failure
Third Rock Pumps $41 Million Into Global Blood Therapeutics
Lorcaserin Makes It Past Panel On The Strength Of Effect In Some Patients
Third Rock Launches Ember Therapeutics With Focus On Obesity And Type 2 Diabetes
Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million
Lotus Tissue Repair Scores $26 Million in Series A Round
Blueprint Medicines Takes $40MM From Third Rock To Build Oncology Platform
Avalon's Sweat Equity


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts